ArticleCancers2019
The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 81 citations in OpenAlex.
- Development and Evaluation of a Phospholipid Complex-Loaded SMEDDS for Enhanced Oral Delivery of H007, a Novel Anti-Hyperlipidemic Drug.Pharmaceutics · 2026Article
- Codelivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity against Melanoma Cells.ACS omega · 2025Article
- MF59-based lipid nanocarriers for paclitaxel delivery: optimization and anticancer evaluation.Scientific reports · 2025Article
- Application of Biomimetic Cell Membrane-Coated Nanocarriers in Cardiovascular Diseases.International journal of nanomedicine · 2025Review
- Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) Nanoparticles as a Targeting Drug Delivery System for Multidrug-Resistant Breast Cancer.International journal of nanomedicine · 2025Article
- Immunocyte membrane-derived biomimetic nano-drug delivery system: a pioneering platform for tumour immunotherapy.Acta pharmacologica Sinica · 2024Review
- Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.Biomarker research · 2024Review
- Cell Membrane-Coated Nanoparticles for Dental, Oral, and Craniofacial Diseases.Research (Washington, D.C.) · 2024Review
- Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications.Beilstein journal of nanotechnology · 2024Article
- Advancements in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Breast Cancer Therapy.Current pharmaceutical design · 2024Review
- Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Clinically Expired Platelet Concentrates as a Source of Extracellular Vesicles for Targeted Anti-Cancer Drug Delivery.Pharmaceutics · 2023Article
- Curcumin-Loaded Platelet Membrane Bioinspired Chitosan-Modified Liposome for Effective Cancer Therapy.Pharmaceutics · 2023Article
- Stem cell membrane-camouflaged targeted delivery system in tumor.Materials today. Bio · 2022Review
- Bioinspired Platelet-like Nanovector for Enhancing Cancer Therapy via P-Selectin Targeting.Pharmaceutics · 2022Article
- Integrative analysis of platelet-related genes for the prognosis of esophageal cancer.World journal of clinical cases · 2022Article
- Cell membrane coated-nanoparticles for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2022Review
- Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel.Pharmaceutics · 2022Article
- Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, AttenuatingBioMed research international · 2022Article
- Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer.Journal of nanobiotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Strategies for the development of anticancer drug delivery systems have undergone a dramatic transformation in the last few decades. Lipid-based drug delivery systems, such as a nanostructured lipid carrier (NLC), are one of the systems emerging to improve the outcomes of tumor treatments. However, NLC can act as an intruder and cause an immune response. To overcome this limitation, biomimicry technology was introduced to decorate the surface of the nanoparticles with various cell membrane proteins. Here, we designed paclitaxel (PT)-loaded nanostructured lipid carrier (PT-NLC) with platelet (PLT) membrane protein because PLT is involved with angiogenesis and interaction of circulating tumor cells. After PLT was isolated from blood using the gravity-gradient method and it was used for coating PT-NLC. Spherical PT-NLC and platelet membrane coated PT-NLC (P-PT-NLC) were successfully fabricated with high encapsulation efficiency (EE) (99.98%) and small particle size (less than 200 nm). The successful coating of PT-NLC with a PLT membrane was confirmed by the identification of CD41 based on transmission electron microscopy (TEM), western blot assay and enzyme-linked immunosorbent assay (ELISA) data. Moreover, the stronger affinity of P-PT-NLC than that of PT-NLC toward tumor cells was observed. In vitro cell study, the PLT coated nanoparticles successfully displayed the anti-tumor effect to SK-OV-3 cells. In summary, the biomimicry carrier system P-PT-NLC has an affinity and targeting ability for tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.